Vansteenkiste, J. F., & Hoffmann, H. (2016). Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): A randomised, double-blind, placebo-controlled, phase 3 trial. The lancet. Oncology, 17(6), . https://doi.org/10.1016/S1470-2045(16)00099-1
Chicago-Zitierstil (17. Ausg.)Vansteenkiste, Johan F., und Hans Hoffmann. "Efficacy of the MAGE-A3 Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resected MAGE-A3-positive Non-small-cell Lung Cancer (MAGRIT): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet. Oncology 17, no. 6 (2016). https://doi.org/10.1016/S1470-2045(16)00099-1.
MLA-Zitierstil (9. Ausg.)Vansteenkiste, Johan F., und Hans Hoffmann. "Efficacy of the MAGE-A3 Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resected MAGE-A3-positive Non-small-cell Lung Cancer (MAGRIT): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet. Oncology, vol. 17, no. 6, 2016, https://doi.org/10.1016/S1470-2045(16)00099-1.